Pretransplant evaluation of a patient with acute intermittent porphyria

S. Turton-Weeks, G. W. Barone, B. J. Gurley, B. L. Ketel, M. L. Lightfoot, S. R. Abul-Ezz, Karl Anderson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The pretransplant evaluation of a patient with a rare diagnosis requires knowledge of the pathophysiology and the transplant literature. A 55-year-old man presented with hypertensive kidney failure and the clinical diagnosis of acute intermittent porphyria. Complications of acute intermittent porphyria, which is a defect of heme production, are due to the accumulation of heme intermediates often precipitated by medications. Based on animal data, cyclosporine is considered unsafe in patients with acute intermittent porphyria. As part of the pretransplant evaluation, the patient received separate trials of tacrolimus and cyclosporine, which did not stimulate his acute intermittent porphyria. Four months after a kidney transplant, the patient still had no signs of rejection or symptoms of acute intermittent porphyria. This is the first documented patient with acute intermittent porphyria who successfully received a kidney transplant using tacrolimus. Because of individual variations, pretransplant testing of calcineurin inhibitors should be continued in patients with acute intermittent porphyria.

Original languageEnglish (US)
Pages (from-to)214-216
Number of pages3
JournalProgress in Transplantation
Volume11
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Acute Intermittent Porphyria
Tacrolimus
Transplants
Heme
Cyclosporine
Kidney
Renal Insufficiency

ASJC Scopus subject areas

  • Transplantation

Cite this

Turton-Weeks, S., Barone, G. W., Gurley, B. J., Ketel, B. L., Lightfoot, M. L., Abul-Ezz, S. R., & Anderson, K. (2001). Pretransplant evaluation of a patient with acute intermittent porphyria. Progress in Transplantation, 11(3), 214-216.

Pretransplant evaluation of a patient with acute intermittent porphyria. / Turton-Weeks, S.; Barone, G. W.; Gurley, B. J.; Ketel, B. L.; Lightfoot, M. L.; Abul-Ezz, S. R.; Anderson, Karl.

In: Progress in Transplantation, Vol. 11, No. 3, 2001, p. 214-216.

Research output: Contribution to journalArticle

Turton-Weeks, S, Barone, GW, Gurley, BJ, Ketel, BL, Lightfoot, ML, Abul-Ezz, SR & Anderson, K 2001, 'Pretransplant evaluation of a patient with acute intermittent porphyria', Progress in Transplantation, vol. 11, no. 3, pp. 214-216.
Turton-Weeks S, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR et al. Pretransplant evaluation of a patient with acute intermittent porphyria. Progress in Transplantation. 2001;11(3):214-216.
Turton-Weeks, S. ; Barone, G. W. ; Gurley, B. J. ; Ketel, B. L. ; Lightfoot, M. L. ; Abul-Ezz, S. R. ; Anderson, Karl. / Pretransplant evaluation of a patient with acute intermittent porphyria. In: Progress in Transplantation. 2001 ; Vol. 11, No. 3. pp. 214-216.
@article{cfcb4923fffa48529b10fc3c10b5a1db,
title = "Pretransplant evaluation of a patient with acute intermittent porphyria",
abstract = "The pretransplant evaluation of a patient with a rare diagnosis requires knowledge of the pathophysiology and the transplant literature. A 55-year-old man presented with hypertensive kidney failure and the clinical diagnosis of acute intermittent porphyria. Complications of acute intermittent porphyria, which is a defect of heme production, are due to the accumulation of heme intermediates often precipitated by medications. Based on animal data, cyclosporine is considered unsafe in patients with acute intermittent porphyria. As part of the pretransplant evaluation, the patient received separate trials of tacrolimus and cyclosporine, which did not stimulate his acute intermittent porphyria. Four months after a kidney transplant, the patient still had no signs of rejection or symptoms of acute intermittent porphyria. This is the first documented patient with acute intermittent porphyria who successfully received a kidney transplant using tacrolimus. Because of individual variations, pretransplant testing of calcineurin inhibitors should be continued in patients with acute intermittent porphyria.",
author = "S. Turton-Weeks and Barone, {G. W.} and Gurley, {B. J.} and Ketel, {B. L.} and Lightfoot, {M. L.} and Abul-Ezz, {S. R.} and Karl Anderson",
year = "2001",
language = "English (US)",
volume = "11",
pages = "214--216",
journal = "Progress in Transplantation",
issn = "1526-9248",
publisher = "InnoVision Communications",
number = "3",

}

TY - JOUR

T1 - Pretransplant evaluation of a patient with acute intermittent porphyria

AU - Turton-Weeks, S.

AU - Barone, G. W.

AU - Gurley, B. J.

AU - Ketel, B. L.

AU - Lightfoot, M. L.

AU - Abul-Ezz, S. R.

AU - Anderson, Karl

PY - 2001

Y1 - 2001

N2 - The pretransplant evaluation of a patient with a rare diagnosis requires knowledge of the pathophysiology and the transplant literature. A 55-year-old man presented with hypertensive kidney failure and the clinical diagnosis of acute intermittent porphyria. Complications of acute intermittent porphyria, which is a defect of heme production, are due to the accumulation of heme intermediates often precipitated by medications. Based on animal data, cyclosporine is considered unsafe in patients with acute intermittent porphyria. As part of the pretransplant evaluation, the patient received separate trials of tacrolimus and cyclosporine, which did not stimulate his acute intermittent porphyria. Four months after a kidney transplant, the patient still had no signs of rejection or symptoms of acute intermittent porphyria. This is the first documented patient with acute intermittent porphyria who successfully received a kidney transplant using tacrolimus. Because of individual variations, pretransplant testing of calcineurin inhibitors should be continued in patients with acute intermittent porphyria.

AB - The pretransplant evaluation of a patient with a rare diagnosis requires knowledge of the pathophysiology and the transplant literature. A 55-year-old man presented with hypertensive kidney failure and the clinical diagnosis of acute intermittent porphyria. Complications of acute intermittent porphyria, which is a defect of heme production, are due to the accumulation of heme intermediates often precipitated by medications. Based on animal data, cyclosporine is considered unsafe in patients with acute intermittent porphyria. As part of the pretransplant evaluation, the patient received separate trials of tacrolimus and cyclosporine, which did not stimulate his acute intermittent porphyria. Four months after a kidney transplant, the patient still had no signs of rejection or symptoms of acute intermittent porphyria. This is the first documented patient with acute intermittent porphyria who successfully received a kidney transplant using tacrolimus. Because of individual variations, pretransplant testing of calcineurin inhibitors should be continued in patients with acute intermittent porphyria.

UR - http://www.scopus.com/inward/record.url?scp=0034823031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034823031&partnerID=8YFLogxK

M3 - Article

C2 - 11949465

AN - SCOPUS:0034823031

VL - 11

SP - 214

EP - 216

JO - Progress in Transplantation

JF - Progress in Transplantation

SN - 1526-9248

IS - 3

ER -